Heterocyclic Compounds

Matches 1 - 50 out of 12,074	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/102078A1	HETEROBIFUNCTIONAL LINKERS AND BIOCONJUGATE MOLECULES This invention provides compounds according to formula (I): wherein A and Za are as defined in the specification. The compounds of formula (I) find use as heterobifunctional linkers. The present invention also provides compounds of formu...
WO/2024/098273A1	ANTI-INFLUENZA VIRUS PHOSPHATE ESTER COMPOUND AND USE THEREOF An anti-influenza virus phosphate ester compound and a use thereof. The phosphate ester compound is a compound represented by formula (I) below or a hydrate, a solvate, an optical isomer, a polymorph, an isotope derivative or a pharmaceu...
WO/2024/098735A1	ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT APPARATUS, AND ELECTRONIC DEVICE The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, and an organic electroluminescent apparatus and an electronic device using same. The organic compound has a struct...
WO/2024/099402A1	INTERMEDIATES AND PROCESS OF COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE Provided are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and us...
WO/2024/099908A1	CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS The invention relates to compounds of formula Iwherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such a...
WO/2024/102810A1	BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...
WO/2024/099907A1	CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS The invention relates to compounds of formula I wherein R1, R2, R3, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such as s...
WO/2024/099400A1	INTERMEDIATES AND PROCESS OF COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparatio...
WO/2024/099395A1	COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE Disclosed herein are novel bifunctional compounds of formula (I) formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and method...
WO/2024/097296A1	ANTI-VIRAL COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2024/094171A1	SUBSTITUTED AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF A substituted aminopyrimidine compound, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, in particular as an EGFR inhibitor and/or degradation agent and the us...
WO/2024/097172A1	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
WO/2024/095012A1	PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS The invention relates to a compound of formula (Ia) and related aspects.
WO/2024/097606A1	AHR AGONISTS The present disclosure relates to certain AHR agonist compounds, for example, having a general formula (I) to pharmaceutical compositions comprising the compounds, and to methods of using the compounds to treat immune-mediated diseases, ...
WO/2024/088189A1	MACROCYCLIC COMPOUND AS CDK9 INHIBITOR AND USE THEREOF The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.
WO/2024/091894A1	PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF The present disclosure is directed to novel PNU Anthracycline Derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the above disclosure. The disclosure is also directed to pharmac...
WO/2024/088307A1	NOVEL PEPTIDYL NITRILE COMPOUND AND USE THEREOF Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
WO/2024/088110A1	HETEROCYCLIC MACROCYCLIC COMPOUND CONTAINING INDAZOLE STRUCTURE AND USED AS PROTEIN KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
WO/2024/090469A1	FUSED PYRIDAZINE DERIVATIVE The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases.　The inventors of th...
WO/2024/089683A1	ANTICANCER DRUG CONJUGATES Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
WO/2024/082645A1	ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC DEVICE The present application relates to the technical field of organic electroluminescence, and relates to an organic compound, an organic electroluminescent device using same, and an electronic device. The organic compound has a structure as...
WO/2024/083980A1	BICYCLIC FERROPORTIN INHIBITORS The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
WO/2024/086296A1	COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...
WO/2024/084390A1	COMPOUNDS FOR THE ACTIVATION OF AMPK Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or periphe...
WO/2024/085661A1	NOVEL TRIHETEROCYCLIC COMPOUNDS Provided are triheterocyclic compounds, and more specifically triheterocyclic compounds useful as KRAS protein inhibitors, and a pharmaceutical composition including the same for treating cancers.
WO/2024/086634A1	HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
WO/2024/083223A1	MACROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...
WO/2024/085036A1	COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC APPLIANCE A compound represented by formula (1) (the symbols in formula (1) are as defined in the description); an organic electroluminescent element containing the compound; and an electronic appliance containing the organic electroluminescent el...
WO/2024/083146A1	COMPOUND BASED ON ORYDALMINE STRUCTURE AND USE THEREOF The present invention relates to a compound of general formula (A) and a pharmaceutical composition thereof. The compound of formula (A) provided in the present invention can be used for preventing and/or treating diseases related to the...
WO/2024/083168A1	OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF Provided herein are oxazepinyl compounds comprising a 6-aza moiety that are useful in the treatment of cancers.
WO/2024/083933A1	2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX 3CR1 There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), (I) and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are modulator...
WO/2024/078263A1	PREPARATION AND USE OF MACROCYCLIC HETEROCYCLIC COMPOUND AS EGFR INHIBITOR The present invention relates to a macrocyclic heterocyclic compound as a selective inhibitor of a clinical mutant of EGFR kinase, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt ther...
WO/2024/078372A1	HETEROCYCLIC SUBSTITUTED PHENOL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Provided are a heterocyclic substituted phenol derivative, a preparation method therefor, and a use thereof. Specifically, provided are compounds of formulas (I-1), (II-1B), (III), and (IV), stereoisomers thereof, pharmaceutically accept...
WO/2024/079128A1	NEW COMPOUNDS, PROCESSES FOR PREPARING THE SAME AND THEIR USE AS DRUGS The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example,  Z is representing a (II)  X is representing a NR5R6 group wherein R5 and R6 are hydrogen,  R1 is represe...
WO/2024/081927A1	COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
WO/2024/078620A1	NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical comp...
WO/2024/074080A1	ANTI-INFLUENZA VIRUS DERIVATIVE AND USE THEREOF Disclosed in the present invention are a highly effective antiviral derivative and a use thereof. The derivative is a compound shown in formula (I-0) or a hydrate, solvate, optical isomer, polymorphic substance, isotope derivative, or ph...
WO/2024/074611A1	PRMT5 INHIBITORS The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
WO/2024/075815A1	8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...
WO/2024/075696A1	IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc.　A compound represented by formula (1) or a pharma...
WO/2024/076693A1	RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA Disclosed herein are compounds of Formula I and methods for using the same for treating or preventing an infection caused by a mycobacterium in a subject in need thereof. The method comprises administering to the subject the compound of ...
WO/2024/067465A1	KIF18A INHIBITOR Provided are a compound useful as a KIF18A inhibitor, a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, a pharmaceutical composition and a preparation comprising the compound or the pharmaceutically acceptable salt,...
WO/2024/068159A1	SYNTHESIS AND CHARACTERIZATION OF CYCLIC HYDROCARBON ESTERS OF EVEROLIMUS This application relates generally to the field of synthesis, formulations and perivascular treatment methods involving cyclic ester derivatives of everolimus.
WO/2024/073507A1	MACROCYCLIC COMPOUNDS AND USES THEREOF Described herein are macrocyclic compounds of Formulas (Al), (BI), and (CI) which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a com...
WO/2024/073587A1	N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF Compounds and methods for inhibiting Nrf2 by activating KEAP1.
WO/2024/072794A1	PYRIDINE CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
WO/2024/067575A1	NITROGEN-CONTAINING POLYCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Disclosed are a nitrogen-containing polycyclic compound, and a pharmaceutical composition and use thereof. The nitrogen-containing polycyclic compound of the present invention is a nitrogen-containing polycyclic compound represented by f...
WO/2024/068926A1	RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, ...
WO/2024/073576A1	4-((2-(3,5-DICHLOROPHENYL)-6-((PYRIMIDIN-5-YL)OXY)PYRIDIN-4-YL)METHYL)PIPERAZINE DERIVATIVES AS FURIN INHIBITORS AND USES THEREOF Provided herein are compounds of Formula (I) which are inhibitors of furin, pharmaceutical compositions containing them, processes for their preparation, and their use in therapy (e.g., for the treatment of respiratory syncytial virus).
WO/2024/061370A1	PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention is a pyrimidine-fused ring compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof. In addition, further disclosed in the prese...

Matches 1 - 50 out of 12,074	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >